Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol

Shang-Hung Chen¹,², Hsiang-Lin Tsai³,⁴, Jeng-Kai Jiang⁵, Yung-Chuan Sung⁶,⁷, Ching-Wen Huang³,⁴, Yu-Min Yeh²,⁸, Li-Tzong Chen¹,²,⁹ and Jaw-Yuan Wang³,⁴,¹⁰,¹¹,¹²*.

Abstract

Background: In the management of patients with RAS wild-type metastatic colorectal cancer (mCRC), anti-epidermal growth factor receptor (EGFR) therapies have demonstrated a clinical benefit, with longer survival. However, the correlation between the emergence of circulating RAS mutations and secondary resistance to anti-EGFR therapies requires further elucidation. In this study, we aim to examine evolutionary changes in RAS mutations through liquid biopsy in patients with mCRC during and after anti-EGFR therapy.

Methods: A total of 120 patients diagnosed with RAS wild-type mCRC will be enrolled in this study. Patients will receive a cetuximab-based infusional 5-fluorouracil regimen as first-line treatment. Cetuximab-based treatment is expected to continue until disease progression, intolerable toxic effects, or withdrawal of consent. Blood samples from enrolled patients will be collected before and then every 3 months during cetuximab-based treatment and also at disease progression. These blood samples will be evaluated for RAS resistance mutations by using the MassARRAY platform. The primary endpoint is the percentage of RAS mutations detected in circulating DNA from patients during cetuximab treatment. The correlation between the tumor response and survival outcomes of these patients and the emergence of circulating RAS mutations will be further analyzed.

Discussion: Liquid biopsy is a powerful technology that can represent tumor heterogeneity in a relatively noninvasive manner. Because RAS mutations play a major role in resistance to anti-EGFR therapy for mCRC, examining evolutionary changes in these mutations during such treatment through liquid biopsy would be useful. After comprehensively analyzing the emergence of circulating RAS mutations and its clinical relevance in this study, our results should provide practical guidance on anti-EGFR therapy for mCRC.

Trial registration: The date of trial registration (NCT03401957) in this study was January 17, 2018.

Keywords: RAS mutation, Metastatic colorectal cancer, Cetuximab, Liquid biopsy

Background

Colorectal cancer (CRC), a neoplasm arising from the large bowel, is a common and lethal disease with approximately 1,100,000 new cases and 550,000 deaths worldwide in 2018 [1]. In Taiwan, CRC is the most commonly diagnosed cancer (15,579 new cases in 2015) and the third most common cause of cancer-related deaths (5687 deaths in 2015) [2]. Nearly 20% of newly diagnosed cases of CRC are metastatic at initial presentation; a certain proportion of patients in early stages would also develop metastases even after curative surgery [3]. Systemic treatment is generally recommended for metastatic CRC (mCRC). In addition to conventional chemotherapy drugs, several agents targeting the molecular drivers of CRC pathogenesis, including signaling pathways mediated by the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor, have been...
applied in such patients, with increasing survival rates [4–8].

Cetuximab is an EGFR-targeted monoclonal antibody with established clinical benefits as a component of first-line treatment for patients with RAS wild-type mCRC [7, 8]. The predictive role of RAS mutations in the clinical responses of mCRC to anti-EGFR therapies has been demonstrated in several pivotal studies [7–11]. RAS belongs to a family of small G proteins, including HRAS, KRAS, and NRAS, which are responsible for ligand-dependent receptor activation. In general, KRAS mutations are found in approximately 40% of patients with CRC, NRAS mutations are about 3%, and HRAS mutations are relatively rare [11, 12]. Mutations at key sites within the RAS family cause constitutive activation of RAS-associated signaling, rendering anti-EGFR therapies ineffective for mCRC. Therefore, the identification of RAS mutations in tumor tissues to determine patients that are more likely to benefit from anti-EGFR therapies has become standard in the pretreatment management of patients with mCRC [12]. Moreover, acquired resistance inevitably appears in some patients after the initial response to cetuximab, thus limiting the clinical benefit of this anti-EGFR antibody. The emergence of RAS mutations is also potentially responsible for acquired resistance to cetuximab in patients with mCRC [13–15]. RAS mutations have been identified after anti-EGFR therapies in approximately 50% of patients with RAS wild-type mCRC [13, 14]. In addition, genetic alterations in BRAF, a downstream effector of the EGFR signaling pathway, have been found in around 5% of patients with CRC. Some meta-analyses have shown that BRAF-mutant CRCs are associated with the low clinical efficacy of anti-EGFR therapies [11, 12]. Accordingly, dynamic monitoring for the emergence of activation mutations of effectors downstream located in EGFR signaling pathway, especially RAS mutations in patients undergoing anti-EGFR therapies can be a useful tool to determine tumor response and ongoing patient care.

During cancer progression, circulating nucleic acids carrying specific genetic alterations of tumor cells (circulating tumor DNA, or ctDNA) from both primary and metastatic sites can enter the bloodstream [16]. Liquid biopsy is a newly developed technique capable of detecting these genetic alterations, especially specific base nucleotide substitutions from ctDNA, through blood sampling. Certain point mutations of tumor cells from circulating free DNA (cfDNA) in the plasma of patients with a given cancer type, including CRC, have been identified [17, 18]. An analysis of cfDNA through liquid biopsy avoids the limitations of tumor tissue-based mutation analysis. Therefore, this minimally invasive technique can offer the advantage of continuously monitoring the major genotype represented in tumor cells with a complex heterogeneity. Nevertheless, substantial challenges remain because ctDNA often represents only a small fraction of total cfDNA [19–21]. Standard sequencing approaches, such as the Sanger sequencing method, can only detect tumor-specific mutations in patients with a heavy tumor burden. A personalized approach using sensitive detection tools, such as next generation sequencing (NGS), is also not feasible in routine clinical practice due to the high cost and demand for qualified research personnel.

More recently, a mass spectrometry-based technique combined with a single-base extension polymerase chain reaction (PCR) has been used to investigate genotyping across a variety of human cancers [22, 23]. This high-throughput technique, called the MassARRAY platform (Sequenom, Brisbane, Australia), can access up to 40 single-nucleotide polymorphisms in a single reaction with satisfactory sensitivity and specificity. Results from other studies have verified the concordance of genotyping in CRC patient-matched plasma and tumor tissue samples using this mass spectrometry platform [23, 24]. Therefore, in this prospective study, we will use this platform to examine RAS mutations in serial blood samples collected from patients with mCRC undergoing cetuximab treatment. To determine a more effective anti-EGFR therapeutic strategy for mCRC, the correlation between the clinical response of tumors to cetuximab and the emergence of resistant mutations will also be analyzed.

Methods/design
Study design
This single-arm, non-interventional, uncontrolled, multicenter study will evaluate the emergence of RAS mutations in patients with mCRC receiving a cetuximab-based regimen as first-line treatment. In this investigator-initiated study, patients diagnosed with RAS wild-type mCRC will be recruited. Patients for whom treatment is planned with a cetuximab-based regimen under the locally approved label will be enrolled. In addition to cetuximab, infusional 5-fluorouracil is required and combination with oxaliplatin or irinotecan is allowed in first-line treatment. On the basis of the best scientific knowledge, clinical practice for each patient is determined entirely by the responsible investigator. This cetuximab-based treatment is expected to continue until disease progression, intolerable toxic effects, or withdrawal of consent. Blood samples from patients enrolled in this study will be collected before the start of cetuximab-based chemotherapy and then every 3 months during first-line treatment. Blood sampling is also required within 3 weeks of disease progression following cetuximab and second-line treatments. The blood samples will be sent to the central laboratory at Taipei Institute of Pathology and evaluated for the RAS genotype by using the MassARRAY technique. Pretreatment tissue sections will also be re-evaluated for the RAS genotype.
by using this technique if a discordance of RAS genotype occurs between the tissue and blood samples of the same patient. This study is briefly outlined in Fig. 1.

**Study objectives**
The primary endpoint is the percentage of RAS mutations detected in the cfDNA of patients with mCRC during first-line cetuximab treatment. The secondary objectives are the following endpoints: 1. duration between the start of cetuximab treatment and the new detection of a RAS mutation; 2. percentage of mutated alleles detected at disease progression; 3. clinical responses and metastasis resection rates during first-line cetuximab treatment; 4. progression-free and overall survival of patients receiving first-line cetuximab treatment; 5. correlations between RAS resistance mutations after cetuximab treatment (occurrence and levels) and clinical survival outcomes; 6. total cetuximab dosage in first-line treatment; and 7. correlations between irinotecan or oxaliplatin dosage and acquired resistance to cetuximab.

**Eligibility criteria**
In this multicenter study, we intend to enroll 120 patients with wild-type RAS mCRC from four participating hospitals, namely Kaohsiung Medical University Hospital, Taipei Veterans General Hospital, Cathay General Hospital, and National Cheng Kung University Hospital. The selection of patients is at the discretion of the investigator. Inclusion and exclusion criteria are listed below.

**Inclusion criteria**
1. Patients with mCRC for whom a cetuximab-based regimen is planned as first-line treatment after considering routine clinical practice, the locally approved label, and the best scientific knowledge. The choice of the chemotherapy regimen for first-line treatment is also at the sole discretion of the investigator, based upon routine clinical practice.
2. Patients aged 20 years and above.
3. Patients pathologically and molecularly diagnosed with wild-type RAS CRC.
4. Patients willing to provide blood samples during the study.
5. Patients willing and able to provide signed informed consent.

**Exclusion criteria**
1. Patients with a history of any anti-EGFR therapy.
2. Contraindications to cetuximab as per the locally approved label.

**Blood sampling**
Blood will be obtained from an arterial or venous line according to standard phlebotomy technique, with a Cell Free DNA collection tube (Roche) used for sampling. Blood specimens will be shipped at room temperature within 24 h, and plasma preparation and cfDNA extraction will be performed within 7 days of sampling at Taipei Institute of Pathology.

**RAS mutation analysis of cfDNA and tissue samples**
Before mutation analysis, cfDNA will be extracted using the Cobas cfDNA sample preparation kit, and a representative tumor sample (primary or metastasis) will be made available for a repeat RAS mutation analysis in case of any discordance between the tumor tissue and cfDNA analyses. Three to five sections of a formalin-fixed paraffin-embedded (FFPE) tissue for DNA extraction will be made using the QIAamp DNA FFPE tissue kit. Mutations will be detected using a MassARRAY platform combined with the single allele base extension reaction (SABER) technique (Agena, San Diego, California, USA). In a SABER reaction using the iPLEX enzyme, SABER terminator mix, and extension primer mix (iPLEX Pro kit, Agena), clinically relevant mutations in KRAS, NRAS and BRAF genes are targeted (Additional file 1: Table S1). After the
addition of a cation exchange resin to remove residual salt from the reactions, a purified primer extension reaction is loaded onto the matrix pad of a SpectroCHIP bioarray (Sequenom) by using a MassARRAY nano-dispenser and assayed on the MassARRAY platform. The mutation peaks are identified as a higher than background intensity compared with a non-mutation sample pool.

Schedule of assessments
Patients will undergo RAS mutation analysis of cfDNA every 3 months during cetuximab-based first-line treatment and within 3 weeks of disease progression after first- and second-line treatments. During the study period, the assessment of patients will be scheduled according to the clinical judgment of the responsible investigator. The tumor response will likewise be assessed from the imaging scan at the investigator’s judgment.

Sample size calculation
The present study aims to identify the frequency of RAS mutations in cfDNA during cetuximab treatment. In earlier studies, 21 and 33% of patients with RAS wild-type CRC at baseline displayed KRAS mutations at week 24 and 26, respectively [13–15]. Sample size is based on test power considerations by using a confidence limit. When the Wilson score method was used, a sample size of 110 produced two-sided 95% confidence intervals (CIs) of 0.169, 0.176, and 0.180 when the sample proportion was 0.300, 0.350, and 0.400, respectively [25]. Taking a 10% dropout rate into account, 120 patients should be enrolled in this study.

Statistical analysis
The National Health Research Institutes is responsible for data management and statistical analysis. In general, descriptive statistics are used in this study. All patients receiving at least 8 weeks of treatment and having at least one post-baseline RAS mutation in their cfDNA will be eligible for clinical efficacy and outcome evaluation (efficacy population). The frequency of RAS mutations will be calculated and presented as a number, percentage, and 95% CI for the efficacy population. Clinical responses to cetuximab treatment will likewise be presented as a frequency, percentage, and 95% CI. Cox proportional hazard models will be used to investigate the effect of RAS mutations on time-to-event endpoints, including progression-free survival (PFS) and overall survival (OS). Other major clinical variables will also be included in these Cox models (e.g., disease characteristics or type of chemotherapy). Kaplan–Meier survival curves will be produced for PFS and OS of patients with and without genetic mutations. Kaplan–Meier methods will also be applied to the onset time of newly detected RAS mutations in cfDNA. The onset time of RAS mutations will be censored in patients without mutations at the last available measurement of cfDNA.

Ethical considerations
The final protocol of this study was approved by the ethics committee of the National Health Research Institutes, with reference number EC1060904. Official approval has also been obtained from the ethics committee of Kaohsiung Medical University Hospital (reference number: KMUHIRB-GII-20170027), Taipei Veterans General Hospital (reference number: 2017–12-003A), Cathay General Hospital (reference number: CGH-P107013), and National Cheng Kung University Hospital (reference number: A-BR-106-045). The study has been registered on the ClinicalTrials.gov website, with identification number NCT03401957. The trial will be performed in accordance with the 7th version of the World Medical Association’s Declaration of Helsinki, the International Council for Harmonization’s E6 (R2) Guideline for Good Clinical Practice, and regulatory laws in Taiwan. Prior to participation in this study, written informed consent will be obtained from each patient.

Discussion
The release of cfDNA into the bloodstream can originate from apoptosis, necrosis, and probably also the active secretion of tumor cells [16, 26]. Although cfDNA would only account for a certain portion of cfDNA in patients with cancer, circulating nucleic acids from tumor cells could be detected through the development of molecular quantification techniques such as NGS and digital PCR (dPCR) [17, 27]. Over the past few years, clinical applications of liquid biopsy, which examines existing genetic alterations through cfDNA, have been widely explored for early diagnosis, recurrence/metastasis monitoring, and prognostic value in patients with a variety of cancers [19, 28, 29]. Apart from such applications, which are similar to conventional tumor markers, another potential advantage of cfDNA is the ability to detect specific genetic variations known to cause resistance to anticancer treatments, especially targeted therapies. This would enable monitoring tumor response and even modifying early treatment in patients during targeted anticancer therapy. The clinical benefits of anti-EGFR therapies have been demonstrated in patients with mCRC; however, mutations in RAS are reportedly linked to primary anti-EGFR therapy resistance [7–11]. Initial retrospective analyses of pivotal studies have shown that activating mutations in KRAS exon 2 are predictive of poor response to anti-EGFR antibodies. Moreover, recent post hoc researches from clinical studies have shown that mutations outside of those in KRAS exon 2, including exons 3 and 4 of KRAS and exons 2, 3 and 4 of NRAS, also own the predictive value of a low response to anti-EGFR
antibodies [11, 12]. Apart from RAS mutations, some studies have demonstrated that genomic alterations in other effectors of EGFR pathway, such as BRAF mutations, can be negative predictive biomarkers for anti-EGFR therapies [11, 12]. Therefore, the research aimed at monitoring the emergence of genomic alterations in effectors of EGFR pathway and elucidating their connection with acquired resistance to anti-EGFR therapies in patients with mCRC is warranted.

Several studies have reported a correlation between the emergence of circulating RAS mutations and the acquisition of resistance to anti-EGFR therapies in patients with mCRC [13, 14, 30, 31]. The potential value of these studies for clinical application is summarized in Table 1. Among patients with RAS wild-type mCRC, the detection rate of RAS mutations in ctDNA was 13–60% when secondary resistance to anti-EGFR therapies is ensured. In a cornerstone study by Misale et al., the onset of KRAS mutations in ctDNA analysis could be detected as early as 10 months prior to disease progression through radiological documentation [14]. However, in another pioneering study by Diaz et al., circulating KRAS mutations generally occurred 5–6 months after anti-EGFR therapy [13]. Overall, the detectable quantity of mutant ctDNA increases gradually during the development of secondary resistance. Nevertheless, a sudden increase in circulating KRAS mutations would be a warning sign. As reported by Toledo et al., fulminant tumor progression clinically follows an abrupt increase in mutant ctDNA [30].

Although a significant association between the emergence of circulating RAS mutations and secondary resistance to anti-EGFR therapies has been revealed by these studies [13, 14, 30, 31], the relatively small number of enrolled patients limits their potential value for clinical application. The retrospective nature of these studies also hinders confidence in the utility of liquid biopsy in monitoring anti-EGFR therapy response. Large prospective clinical studies are necessary to elucidate the clinical relevance of using ctDNA to dynamically monitor resistant genetic variants during anti-EGFR therapies. Therefore, we designed this prospective study to investigate the emergence of RAS mutations in the ctDNA of patients with RAS wild-type mCRC receiving anti-EGFR therapy as first-line treatment. To the best of our knowledge, this study, which intends to recruit 120 patients, has the largest patient enrollment among the ongoing trials of the efficacy of liquid biopsy in mCRC. To further explore the clinical relevance of liquid biopsy, tumor response to anti-EGFR therapies and survival outcomes will be statistically compared with serial alterations of circulating RAS mutations in these patients. The development of drug resistance within tumor cells is believed to be a dynamic process of ecological evolution [32]. Consecutive changes in mutant ctDNA after the discontinuation of anti-EGFR therapies still remain unclear. This study will analyze the mutant ctDNA of patients with mCRC not only during anti-EGFR therapy as first-line treatment but also at disease progression after second-line treatment. Rechallenge with a previously administered cetuximab-based regimen has been reported to alleviate tumor progression in patients with refractory mCRC [33]. Evolutionary changes of the mutation burden in ctDNA revealed by this current study can offer a fundamental rationale for an anti-EGFR therapy rechallenge strategy.

Two main techniques for detecting genetic variations in ctDNA are currently in use. The first incorporates a nontargeted method using genome-wide analysis of ctDNA, such as an NGS-based technique. In a recent retrospective analysis from the ASPECT study, Peeters et al. have reported that higher mutant allele frequencies in EGFR pathway genes detected in cfDNA, using an

| Table 1 Summary of studies monitoring RAS mutations in ctDNA of mCRC patients receiving anti-EGFR therapies |
|---------------------------------------------------------------|
| Reference          | Methods for ctDNA measurement | Patients (n) | Previous chemotherapy exposure | Anti-EGFR therapy | Rate of detected circulating RAS mutations during treatment (%) | Potential clinical value |
|--------------------|-------------------------------|--------------|-------------------------------|-------------------|---------------------------------------------------------------|--------------------------|
| Diaz LA et al. [13]| BEAMing                       | 28           | yes                           | panitumumab       | 38                                                            | Circulating KRAS mutations generally occurred 5–6 months after anti-EGFR therapy. |
| Misale S et al. [14]| Pyrosequencing or BEAMing     | 10           | yes                           | cetuximab or panitumumab | 60                                                            | Circulating KRAS mutations were frequently detected in acquired resistance to anti-EGFR therapies. |
| Toledo RA et al. [30]| BEAMing                      | 23           | no                            | cetuximab         | 13                                                            | Abrupt increase in mutant ctDNA correlated with eminent clinical deterioration. |
| Vidal J et al. [31]| BEAMing                       | 18           | unknown                       | cetuximab or panitumumab | 39                                                            | Circulating RAS mutations correlated with acquired resistance to anti-EGFR therapies. |
NGS-based technique, correop with poor outcome of patients with mCRC receiving anti-EGFR antibodies [18]. Although this approach can provide plentiful genetic information, its lower cost-effectiveness would limit its utilization in clinical practice, especially when distinct genetic variants are to be tested. The second technique involves a targeted approach including the analysis of known genetic variants, such as a dPCR-based technique. This approach offers more sensitive detection of the specific mutant ctDNA that is the focus of research. However, a lack of high-throughput analysis is one major drawback of such dPCR-based techniques. Recently, the MassARRAY platform, an approach integrating a mass spectrometry-based technique with single-base extension PCR, has been developed for liquid biopsy applications. This integrated technique could provide the advantage of high-throughput detection of multiplex genetic variations [24]. The sensitivity of mutant ctDNA detection in this technique was comparable to that of dPCR-based techniques in patients with CRC [34]. Therefore, the MassARRAY platform is employed in this study to analyze RAS mutations in the ctDNA of patients during and after anti-EGFR therapy.

In summary, this prospective study is designed to investigate the emergence of RAS mutations in the ctDNA of patients with RAS wild-type mCRC during a cetuximab-based regimen as first-line treatment and at disease progression after cetuximab and second-line treatments. To determine potential clinical applications, dynamic alterations of circulating RAS mutations will be correlated with the clinical outcomes of these patients. The results of this study will offer substantial, valuable information for an anti-EGFR therapeutic strategy in patients with mCRC.

Additional file

**Additional file 1:** Table S1. The list of activation mutations detected using the MassARRAY system. (DOCX 17 kb)

Abbreviations
ctDNA: Circulating free DNA; CI: Confidence interval; CRC: Colorectal cancer; ctDNA: Circulating tumor DNA; dPCR: Digital PCR; EGFR: Epidermal growth factor receptor; FFPE: Formalin-fixed paraffin-embedded; mCRC: Metastatic colorectal cancer; NGS: Next generation sequencing; OS: Overall survival; PCR: Polymerase chain reaction; PFS: Progression-free survival; SABER: Single allele base extension reaction

Acknowledgements
Not Applicable.

Authors' contributions
Conception and design: SHC, LTC, and JYW; data acquisition: SHC, HLT, IKJ, YCS, CWH, YMY, and JYW; data analysis and interpretation: SHC, LTC, and JYW; drafting the article: SHC and JYW; final approval of manuscript: all authors.

Funding
This study has received funding from Merck Ltd. and is partly supported by the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, R.O.C. This study is also supported by grants through funding from the Ministry of Science and Technology (MOST108–2321-B-037-001, MOST107–2321-B-037-003, MOST107–2314-B-037–116, MOST107–2314-B-037–022-MY2, MOST107–2314-B-037–023-MY2 and the Ministry of Health and Welfare (MOHW107–TDU-B-212–123006, MOHW107–TDU-B-212–114026B, MOHW108–TDU-B-212–133006, MOHW108–TDU-B-212–124026) funded by Health and welfare surcharge of tobacco products, the Kaohsiung Medical University Hospital (KMUH107–7R28, KMUH107–7R29, KMUH107–7R30, KMUH107–7M22, KMUH107–7M23), KMUH510701, KMUH510706, KMUH510710, and Center for Cancer Research, Kaohsiung Medical University (KMU-T108A04).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
This study will recruit 120 patients with mCRC from four medical institutions in Taiwan (Kaohsiung Medical University Chung-Ho Memorial Hospital, Taipei Veterans General Hospital, Cathay General Hospital, and National Cheng Kung University Hospital). The study has been approved by the ethics committee of the National Health Research Institutes (reference number: EC1060004), Kaohsiung Medical University Hospital (reference number: KMUHIRB-GIL-20170027), Taipei Veterans General Hospital (reference number: 2017–12–003A), Cathay General Hospital (reference number: CGHP107013), and National Cheng Kung University Hospital (reference number: A-BR106-045). Written informed consent will be obtained from all patients before participation in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. 2Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 3Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Kaohsiung, Taiwan. 4Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 5Division of Colon & Rectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 6Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, National Cheng Kung University, Kaohsiung, Taiwan. 7Division of Hematology/Oncology, Internal Medicine, Cathay General Hospital, Taipei, Taiwan. 8Graduate Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 9Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 10Graduate Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 11Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 12Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan.

Received: 30 May 2018 Accepted: 12 June 2019
Published online: 28 June 2019

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. The website of Health Promotion Administration, Ministry of Health and Welfare, Taiwan. Available at https://www.hpa.gov.tw/Pages/Usrit.aspx?nid=119. Accessed 28 May 2018.
3. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, D'Angio RB, Grothey A, Lenz HI, Meropol NJ, Ramanathan RK, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12(1):38–50.
4. Cunningham D, Humbert Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(18):1337–45.

5. Douillard JY, Siena S, Cassidy J, Tabernero J, Burke S, Barugel M, Peeters M, Cunningham D, Jassem J, et al. Randomized, phase II trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705.

6. Hunwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffin S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

7. Van Cutsem E, Köhne CH, Hiort E, Zaluski J, Chang Chien CR, Makhson N, Fleitas T, Urcia-Cardehosa MJ, Montgomery C, Alonso E, Navarro S, Burgues O, Vivancos A, Gejali J, Perez-Fidalgo JA, et al. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget. 2016;7(16):22543–55.

8. Lin JK, Lin PC, Lin CH, Jiang JK, Yang SH, Liang WY, Chen WS, Chang SC. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 2014;21 Suppl 4:S688–69.

9. Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey A, Goodman SN, David KA, Juhl H. Detection and quantification of DNA in serum and plasma of patients with colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.

10. Fornarò L, Lonardò S, Masi G, Loquai F, Bergamo F, Salvatore L, Cremolini C, Schirpina M, Vivaldi C, Aprilé G, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013;24(8):2062–7.

11. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Koutoula V, Papamichael D, Laurent-Puig P, et al. Emergence of KRAS mutations and acquired resistance to antiEGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–7.

12. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Koutoula V, Papamichael D, Laurent-Puig P, et al. KRAS gene mutation following the administration of cetuximab: a case report. JSMO-ESMO initiative endorsed by CSCO, KACC, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–50.

13. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):530–37.

14. Sikora E, Yanger G, Robor S, Scala E, Janakiraman M, Liiskä D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget. 2016;7(16):22543–55.

15. Lin JK, Lin PC, Lin CH, Jiang JK, Yang SH, Liang WY, Chen WS, Chang SC. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 2014;21 Suppl 4:S688–69.

16. Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey A, Goodman SN, David KA, Juhl H. Detection and quantification of DNA in serum and plasma of patients with colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.

17. Beije N, Helmiør JC, Weerts MJ, Beaufort CM, Wijggen MA, Marziali A, Verhoeof C, Sleijfer S, Jansen MP, Martens JW. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA in a primary tumor and metastases from patients undergoing resection of colorectal liver metastases. Mol Oncol. 2016;10(6):1575–84.

18. Dehli F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo S, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.

19. Kin C, Kishida E, Poultides GA, Visser BC, Jeffrey SS. Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev Mol Diagn. 2013;13(6):581–99.

20. Toledo RA, Cubillo A, Vega E, Gaardal E, Alvarez R, de la Varga LU, Pascual J, Sánchez G, Samo F, Prieto SH, et al. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFOX-cetuximab. Oncotarget. 2017;8(21):35289–300.

21. Vidal J, Muñoz L, Dalmaases J, Fines E, Edelstein D, Iglésies M, Orillo L, Abalo A, Rodríguez C, Brozos E, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28(6):1325–32.

22. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of cellular resistance mechanisms in colorectal cancer. EMBO J. 2013;32(6):709–14.

23. Santini D, Vincenzi B, Addoro R, Carulli C, Masì G, Scartozzi M, Mancuso A, Baccarani T, Buonadonna G, et al. Clinical definition of actionable alterations in plasma DNA from patients with metastatic colorectal cancer and patients undergoing treatment with cetuximab. JAMA Oncol. 2017;3(9):1221–6.

24. Bissell DM, Weinberg RA, Bowers LA, Chin N, Hahn WC, Minna JD, Scher HI, Hanahan D, Lengauer C, et al. Molecular profiling of plasma DNA in patients with metastatic colorectal cancer: based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 2014;21 Suppl 4:S688–69.

25. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. New York: Wiley; 2003.

26. Stroun M, Luytje J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313(1–2):113–21.

27. Béjiène N, Helmiør JC, Weerts MJ, Beaufort CM, Wijggen MA, Marziali A, Verhoeof C, Sleijfer S, Jansen MP, Martens JW. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA in a primary tumor and metastases from patients undergoing resection of colorectal liver metastases. Mol Oncol. 2016;10(6):1575–84.

28. Dehli F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo S, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.

29. Kin C, Kishida E, Poultides GA, Visser BC, Jeffrey SS. Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev Mol Diagn. 2013;13(6):581–99.

30. Toleda RA, Cubillo A, Vega E, Gaardal E, Alvarez R, de la Varga LU, Pascual J, Sánchez G, Samo F, Prieto SH, et al. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFOX-cetuximab. Oncotarget. 2017;8(21):35289–300.

31. Vidal J, Muñoz L, Dalmaases J, Fines E, Edelstein D, Iglésies M, Orillo L, Abalo A, Rodríguez C, Brozos E, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28(6):1325–32.

32. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of cellular resistance mechanisms in colorectal cancer. EMBO J. 2013;32(6):709–14.

33. Santini D, Vincenzi B, Addoro R, Carulli C, Masì G, Scartozzi M, Mancuso A, Baccarani T, Buonadonna G, et al. Clinical definition of actionable alterations in plasma DNA from patients with metastatic colorectal cancer and patients undergoing treatment with cetuximab. JAMA Oncol. 2017;3(9):1221–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.